Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD123+CLL-1 and CD7 CAR-T in R/R AML
NCT07201727Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, CAR-T Cells, Engineered Antibody Formats
01
Overview
Phase 1, open-label, single-arm trial of JY017 and JY008 in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Adverse Events at 2 years. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
JY017JY008
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07201727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201727.